Mitiglinide calcium hydrate (KAD-1229) is an insulinotropic agent. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.
KAD-1229 Calcium Hydrate (Mitiglinide calcium dihydrate) could binds to sulfonylurea receptors and inhibits the activity of ATP-sensitive K+ channel in MIN 6 cells. Antidiabetic.
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia.
Mitiglinide Calcium hydrate (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load[2].
| Animal Model: | Pregnant Wistar rats (12 weeks)[2] |
| Dosage: | 0.3 mg/kg, 1 mg/kg, 3 mg/kg |
| Administration: | Oral administration |
| Result: | Dose-dependently suppressed AUCglucose levels. |
